Novo Nordisk reported that its Wegovy pill leads to significantly greater average weight loss and fewer side effects compared to Eli Lilly's newly approved rival, Foundayo. The comparison is based on previously published studies, with Wegovy showing about 16.6% weight loss versus Foundayo's 12.4%. Despite Foundayo's easier dosing without food restrictions, Wegovy has seen rapid prescription growth since its U.S. launch. The competition highlights the growing market for oral weight-loss drugs, with patient preferences and side-effect profiles shaping future uptake. Analysts note that Foundayo's sales expectations have been revised down, and upcoming Medicare coverage expansions could influence market dynamics.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
